vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and HERITAGE COMMERCE CORP (HTBK). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $53.6M, roughly 1.4× HERITAGE COMMERCE CORP). HERITAGE COMMERCE CORP runs the higher net margin — 28.2% vs -121.9%, a 150.1% gap on every dollar of revenue. On growth, HERITAGE COMMERCE CORP posted the faster year-over-year revenue change (15.6% vs -6.2%). HERITAGE COMMERCE CORP produced more free cash flow last quarter ($61.3M vs $9.6M). Over the past eight quarters, HERITAGE COMMERCE CORP's revenue compounded faster (12.8% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

The United States Chamber of Commerce (USCC) is a business association advocacy group and is the largest lobbying group in the United States. The group was founded in April 23, 1912, out of local chambers of commerce at the urging of President William Howard Taft and his secretary of commerce and labor Charles Nagel. President Taft's belief was that the "government needed to deal with a group that could speak with authority for the interests of business."

HCAT vs HTBK — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.4× larger
HCAT
$74.7M
$53.6M
HTBK
Growing faster (revenue YoY)
HTBK
HTBK
+21.8% gap
HTBK
15.6%
-6.2%
HCAT
Higher net margin
HTBK
HTBK
150.1% more per $
HTBK
28.2%
-121.9%
HCAT
More free cash flow
HTBK
HTBK
$51.7M more FCF
HTBK
$61.3M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HTBK
HTBK
Annualised
HTBK
12.8%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
HTBK
HTBK
Revenue
$74.7M
$53.6M
Net Profit
$-91.0M
$15.1M
Gross Margin
Operating Margin
-115.3%
41.0%
Net Margin
-121.9%
28.2%
Revenue YoY
-6.2%
15.6%
Net Profit YoY
-340.3%
42.3%
EPS (diluted)
$-1.29
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
HTBK
HTBK
Q4 25
$74.7M
$53.6M
Q3 25
$76.3M
$50.0M
Q2 25
$80.7M
$47.8M
Q1 25
$79.4M
$46.1M
Q4 24
$79.6M
$46.4M
Q3 24
$76.4M
$42.2M
Q2 24
$75.9M
$41.7M
Q1 24
$74.7M
$42.1M
Net Profit
HCAT
HCAT
HTBK
HTBK
Q4 25
$-91.0M
$15.1M
Q3 25
$-22.2M
$14.7M
Q2 25
$-41.0M
$6.4M
Q1 25
$-23.7M
$11.6M
Q4 24
$-20.7M
$10.6M
Q3 24
$-14.7M
$10.5M
Q2 24
$-13.5M
$9.2M
Q1 24
$-20.6M
$10.2M
Gross Margin
HCAT
HCAT
HTBK
HTBK
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
HTBK
HTBK
Q4 25
-115.3%
41.0%
Q3 25
-22.9%
41.1%
Q2 25
-46.0%
18.7%
Q1 25
-25.4%
35.4%
Q4 24
-22.0%
31.8%
Q3 24
-17.9%
34.3%
Q2 24
-20.8%
31.3%
Q1 24
-30.5%
34.2%
Net Margin
HCAT
HCAT
HTBK
HTBK
Q4 25
-121.9%
28.2%
Q3 25
-29.1%
29.4%
Q2 25
-50.8%
13.4%
Q1 25
-29.9%
25.2%
Q4 24
-26.0%
22.9%
Q3 24
-19.3%
24.9%
Q2 24
-17.8%
22.1%
Q1 24
-27.6%
24.1%
EPS (diluted)
HCAT
HCAT
HTBK
HTBK
Q4 25
$-1.29
$0.25
Q3 25
$-0.32
$0.24
Q2 25
$-0.59
$0.10
Q1 25
$-0.35
$0.19
Q4 24
$-0.33
$0.17
Q3 24
$-0.24
$0.17
Q2 24
$-0.23
$0.15
Q1 24
$-0.35
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
HTBK
HTBK
Cash + ST InvestmentsLiquidity on hand
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$708.6M
Total Assets
$502.6M
$5.8B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
HTBK
HTBK
Q4 25
$95.7M
Q3 25
$91.5M
Q2 25
$97.3M
Q1 25
$342.0M
Q4 24
$392.0M
Q3 24
$387.3M
Q2 24
$308.3M
Q1 24
$327.8M
Total Debt
HCAT
HCAT
HTBK
HTBK
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
HTBK
HTBK
Q4 25
$245.8M
$708.6M
Q3 25
$331.9M
$700.0M
Q2 25
$347.5M
$694.7M
Q1 25
$376.8M
$696.2M
Q4 24
$365.2M
$689.7M
Q3 24
$355.0M
$685.4M
Q2 24
$357.0M
$679.2M
Q1 24
$357.2M
$676.3M
Total Assets
HCAT
HCAT
HTBK
HTBK
Q4 25
$502.6M
$5.8B
Q3 25
$587.1M
$5.6B
Q2 25
$616.2M
$5.5B
Q1 25
$891.5M
$5.5B
Q4 24
$858.9M
$5.6B
Q3 24
$813.0M
$5.6B
Q2 24
$691.7M
$5.3B
Q1 24
$695.1M
$5.3B
Debt / Equity
HCAT
HCAT
HTBK
HTBK
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
HTBK
HTBK
Operating Cash FlowLast quarter
$9.9M
$61.7M
Free Cash FlowOCF − Capex
$9.6M
$61.3M
FCF MarginFCF / Revenue
12.9%
114.3%
Capex IntensityCapex / Revenue
0.4%
0.7%
Cash ConversionOCF / Net Profit
4.08×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
HTBK
HTBK
Q4 25
$9.9M
$61.7M
Q3 25
$-464.0K
$18.9M
Q2 25
$-9.0M
$8.0M
Q1 25
$280.0K
$14.8M
Q4 24
$-3.5M
$39.0M
Q3 24
$6.2M
$5.3M
Q2 24
$1.6M
$10.5M
Q1 24
$10.3M
$7.3M
Free Cash Flow
HCAT
HCAT
HTBK
HTBK
Q4 25
$9.6M
$61.3M
Q3 25
$-719.0K
$18.8M
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
$37.3M
Q3 24
$5.5M
$4.9M
Q2 24
$1.3M
$9.9M
Q1 24
$10.1M
$6.9M
FCF Margin
HCAT
HCAT
HTBK
HTBK
Q4 25
12.9%
114.3%
Q3 25
-0.9%
37.7%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
80.5%
Q3 24
7.2%
11.6%
Q2 24
1.7%
23.6%
Q1 24
13.5%
16.4%
Capex Intensity
HCAT
HCAT
HTBK
HTBK
Q4 25
0.4%
0.7%
Q3 25
0.3%
0.1%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
3.5%
Q3 24
0.9%
1.0%
Q2 24
0.4%
1.6%
Q1 24
0.3%
1.0%
Cash Conversion
HCAT
HCAT
HTBK
HTBK
Q4 25
4.08×
Q3 25
1.28×
Q2 25
1.25×
Q1 25
1.28×
Q4 24
3.67×
Q3 24
0.50×
Q2 24
1.14×
Q1 24
0.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

HTBK
HTBK

Segment breakdown not available.

Related Comparisons